Transchem
148.30
-4.60(-3.01%)
Market Cap₹181.47 Cr
PE Ratio63.71
IndustryHealthcare
Company Performance:
1D-3.01%
1M-17.27%
6M+269.64%
1Y+221.20%
5Y+645.23%
View Company Insightsright
More news about Transchem
07Aug 25
Transchem Limited Reports 40% Drop in Q1 Net Profit Amid Revenue Decline
Transchem Limited (BSE: 500422) reported a significant decline in financial performance for Q1 2025. Total income decreased by 33.77% to ₹163.58 lakhs, while net profit fell by 40.24% to ₹99.33 lakhs compared to Q1 2024. The company reported no revenue from operations, with income solely from other sources. Despite the revenue decline, total expenses remained relatively stable at ₹28.48 lakhs. Basic EPS decreased to ₹0.81 from ₹1.36 in the previous year. The company's paid-up equity share capital stands at ₹1,224 lakhs, with other equity at ₹6,707.54 lakhs as of March 31.
 no imag found
Transchem
148.30
-4.60
(-3.01%)
1 Year Returns:+221.20%
Industry Peers
Sun Pharmaceutical
1,715.70
(+0.27%)
Divis Laboratories
6,159.00
(-3.56%)
Torrent Pharmaceuticals
4,072.30
(+0.38%)
Cipla
1,326.20
(-1.76%)
Dr Reddys Laboratories
1,271.30
(+0.08%)
Lupin
2,198.20
(-0.49%)
Zydus Life Science
920.90
(+2.52%)
Mankind Pharma
2,074.30
(-0.61%)
Alkem Laboratories
5,835.50
(-0.93%)
Aurobindo Pharma
1,149.10
(+0.22%)